Carbon dioxide removal with PrismaLung in patients with respiratory failure in intensive care unit.

Not Applicable

• Conditions: Acute respiratory failure; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12624000070538
• Lead Sponsor: Peninsula Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-01-29
• Last Update Posted: 5 February 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Adult patients (18 years or older) with diagnosis of ARDS as per the Berlin Definition.(Ref Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012; 307: 2526-33.)
2. Driving pressure ( P) > 14 and/or Plateau >/= 25 (P is calculated using as plateau pressure minus positive end-expiratory pressure). (Ref: Combes A, Auzinger G, Capellier G, et al. ECCO2R therapy in the ICU: consensus of a European round table meeting. Critical Care. 2020; 24: 490)
3. Respiratory rate > 20 breaths per minute
4. pH < 7.25 and PaCO2 >45

Exclusion Criteria

1. ARDS lasting more than 72 hours at the time of inclusion
2. High pressure (Plateau pressure >30 cm H2O) or high FiO2 (>0·8) ventilation for more than 168 h (7 days);
3. Severe hemodynamic instability as defined by ongoing arrhythmias that is not responsive to treatment
4 Contraindication to limited anticoagulation
5. Treatment limitation including not for resuscitation and not for reintubation
6. Patients with potentially irreversible respiratory failure

Study & Design

• Study Type: Observational
• Study Design: Not specified